Hjem › Astrocytom › Ohio
Astrocytom kliniske forsøg i Ohio
8 studier for Astrocytom søger deltagere på steder i Ohio.
Byer i Ohio
Officiel studietekst (engelsk)
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Ohio State University Comprehensive Cancer Center, Columbus
- University of Cincinnati Cancer Center-West Chester, West Chester
RekruttererFase 3
Alder 12 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07215910Targeted Pediatric High-Grade Glioma Therapy
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RekruttererObservationsstudie
12 Months – 39 Years · Alle køn · Opdateret 8. sep. 2026 · NCT05839379Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT06860594Study of Olutasidenib and Temozolomide in HGG
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RekruttererFase 2
Alder 12 til 39 · Alle køn · Opdateret 1. sep. 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Cleveland Clinic, Cleveland
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT05303519Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RekruttererTidlig fase 1Frivillige med god helbredstilstand velkomne
Alder 1 til 21 · Alle køn · Opdateret 29. jun. 2026 · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RekruttererFase 2
12 Months – 39 Years · Alle køn · Opdateret 29. maj 2026 · NCT05843253Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
- The Cleveland Clinic, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 25. jun. 2025 · NCT05879367Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.